Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis.

Autor:	Bradley JS; From the Division of Infectious Diseases, Rady Children's Hospital San Diego, San Diego, CA.; Division of Pediatric Infectious Diseases, University of California San Diego, La Jolla, CA., Arrieta AC; Children's Hospital of Orange County, Orange, CA., Digtyar VA; Dnipropetrovsk Regional Children's Clinical Hospital, Dnipropetrovsk, Ukraine., Popejoy MW; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Grandhi A; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Bokesch P; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Hershberger E; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Dorr MB; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Tan CM; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Murata Y; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Wolf DJ; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ., Bensaci M; Merck Research Laboratories, Merck & Co, Inc., Kenilworth, NJ.
Jazyk:	angličtina
Zdroj:	The Pediatric infectious disease journal [Pediatr Infect Dis J] 2020 Sep; Vol. 39 (9), pp. 814-823.
DOI:	10.1097/INF.0000000000002790
Abstrakt:	Background: We prospectively evaluated efficacy and safety of daptomycin versus active comparator in children with acute hematogenous osteomyelitis (AHO). Methods: Randomized, controlled, double-blind, global, multicenter, phase 3 trial. Patients 1-17 years of age with suspected/confirmed AHO requiring hospitalization and intravenous therapy were randomized 1:1 to intravenous daptomycin (once-daily, age-adjusted doses) or comparator (vancomycin, nafcillin or equivalent) ≥4 days, followed by oral therapy (14-42 days total). Primary endpoint: protocol-defined clinical improvement by Day 5 in the modified intention-to-treat (MITT) population (confirmed AHO, ≥1 dose of study treatment); differences between study arms were evaluated using a prespecified 15% noninferiority margin for daptomycin. Results: Seventy-three patients per arm received treatment. Pathogens were isolated from 62% of patients (83% methicillin-susceptible Staphylococcus aureus, 9% methicillin-resistant S. aureus [MRSA]). Clinical improvement by Day 5 was observed in 55/71 (78%) daptomycin- and 58/70 (83%) comparator-treated MITT patients (95% confidence interval [CI]: -19.4, 7.4). This difference was not statistically significant; however, daptomycin did not meet the prespecified 15% noninferiority margin, since the lower bound of the 95% CI extended below 15%. Overall, 82% of daptomycin and 87% of comparator patients achieved clinical cure at the test-of-cure visit (secondary endpoint). More comparator patients had treatment-emergent (63% vs. 46%) and treatment-related (18% vs. 7%) adverse events. Conclusions: Differences between daptomycin and comparator for the primary endpoint were not statistically significant; however, prespecified noninferiority criteria for daptomycin were not met. With insufficient cases of confirmed MRSA, we could not evaluate daptomycin for MRSA AHO. Our nonvalidated protocol design yields valuable information for implementing future trials in AHO (ClinicalTrials.gov NCT01922011).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu